Filing Flows › Xeris Biopharma Holdings (XERS) › R&D spending
Xeris Biopharma Holdings (XERS) R&D spending by quarter
Xeris Biopharma Holdings' R&D spending was $11.1M in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 7 quarters it ranged from $7.5M (Q3 2025) to $11.1M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $11.1M | +4% | +48% |
| Q2 2026 | $10.7M | +21% | +32% |
| Q1 2026 | $8.8M | +12% | +13% |
| Q4 2025 | $7.9M | +5% | — |
| Q3 2025 | $7.5M | -7% | — |
| Q2 2025 | $8.1M | +4% | — |
| Q1 2025 | $7.8M | — | — |
Q3 2026 at a glance
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xeris Biopharma Holdings' R&D spending?
Xeris Biopharma Holdings' R&D spending was $11.1M in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Xeris Biopharma Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $7.5M (Q3 2025) to $11.1M (Q3 2026).
Q3 2026 results → · How Xeris Biopharma Holdings makes money →